1 |
Abella JV, Park M (2009). Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab, 296, 973-84.
DOI
ScienceOn
|
2 |
Burgess AW (2008). EGFR family: structure physiology signaling and therapeutic targets. Growth Factors, 26, 263-74.
DOI
ScienceOn
|
3 |
Castillo L, Etienne-Grimaldi MC, Fischel JL, et al (2004). Pharmacological background of EGFR targeting. Ann Oncol, 15, 1007-12.
DOI
ScienceOn
|
4 |
de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J (2001). c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytotic route. J Cell Science, 114, 2167-78.
|
5 |
de Melker AA, van der Horst G, Borst J (2004). Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. J Biol Chem, 279, 55465-73.
DOI
ScienceOn
|
6 |
El-Rayes BF, LoRusso PM (2004). Targeting the epidermal growth factor receptor. Bri J Cancer, 91, 418-24.
DOI
ScienceOn
|
7 |
Fukazawa T, Miyake S, Bandi V, Band H (1996). Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) Stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem, 271, 14554-9.
DOI
ScienceOn
|
8 |
Glogowska A, Stetefeld J, Weber E, et al (2012). Epidermal growth factor cytoplasmic domain affects erbb protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells. Neoplasia, 14, 336-409.
|
9 |
Han W, Zhang T, Yu H, Foulke JG, Tang CK (2006). Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther, 5, 1361-8.
DOI
|
10 |
Hosaka T, Inoue F, Ando K, et al (2007). Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl. Anticancer Res, 27, 2253-64.
|
11 |
Huang F, Sorkin A (2005). Growth factor receptor binding protein 2 mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol Biol Cell, 16, 1268-81.
DOI
ScienceOn
|
12 |
Huang F, Goh LK, Sorkin A (2007). EGF receptor ubiquitination is not necessary for its internalization. PNAS, 104, 16904-9.
DOI
ScienceOn
|
13 |
Jayaraman B, Valiathan GM, Jayakumar K, et al (2012). Lack of mutation in p53 and H-ras genes in phenytoin induced gingival overgrowth suggests its non cancerous nature. Asian Pac J Cancer Prev, 13, 5535-8.
DOI
ScienceOn
|
14 |
Kim YT, Park SW, Kim JW (2002). Correlation between expression of EGFR and the prognosis of patients with cervical cancer. Gynecol Oncol, 87, 84-9.
DOI
ScienceOn
|
15 |
Kirisits A, Pils D, Krainer M (2007). Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. nt J Biochem Cell Biol, 39, 2173-82.
DOI
ScienceOn
|
16 |
Kirkegaard T, Jaattela M (2009). Lysosomal involvement in cell death and cancer. Biochim Biophys Acta, 1793, 746-54.
DOI
ScienceOn
|
17 |
Leahy DJ (2004). Structure and Function of the Epidermal Growth Factor (egf/erbb) family of receptors. Adv Protein Chem, 68, 1-27.
DOI
ScienceOn
|
18 |
Lipkowitz S (2002). The role of the ubiquitination-proteasome pathway in breast cancer Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res, 5, 8-15.
DOI
|
19 |
McMillen E, Ye F, Li G, Wu Y, Kin G et al (2010). Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res, 36, 531-7.
DOI
ScienceOn
|
20 |
Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S et al (2010). Heterozygous germline mutations in the CBL tumorsuppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet, 87, 250-7.
DOI
ScienceOn
|
21 |
Murugan AK, Munirajan AK, Tsuchida N (2012). Ras oncogenes in oral cancer: the past 20 years. Oral Oncol, 48, 383-92.
DOI
ScienceOn
|
22 |
Normanno N, De Luca A, Bianco C, et al (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 336, 2-16.
|
23 |
Ogiso H, Ishitani R, Nureki O, et al (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110, 775-87.
DOI
ScienceOn
|
24 |
Pennock S, Wang Z (2008). A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Molecular and Cell Biology, 28, 3020-37.
DOI
ScienceOn
|
25 |
Rajendran S, Muthupalani RS, Ramanathan A (2013). Lack of RING finger domain (RFD) Mutations of the c-Cbl gene in oral squamous cell carcinomas in Chennai, India. Asian Pac J Cancer Prev, 14, 1073-5.
DOI
ScienceOn
|
26 |
Rubin C, Gur G, Yarden Y (2005). Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res, 15, 66-71.
DOI
ScienceOn
|
27 |
Sigismund S, Confalonieri S, Ciliberto A, et al (2012). Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev, 92, 273-366.
DOI
ScienceOn
|
28 |
Soonthornthum T, Arias-Pulido H, Joste N, et al (2011). Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol, 10, 2166-78.
|
29 |
Visser Smit GD, Place TL, Cole SL, et al (2009). Cbl controls EGFR fate by regulating early endosome. Sci Signal, 2, 86.
|
30 |
Valiathan GM, Thenumgal SJ, Jayaraman B, et al (2012). Common docking domain mutation E322K of the ERK2 gene is infrequent in oral squamous cell carcinomas. Asian Pac J Cancer Prev, 13, 6155-7.
DOI
ScienceOn
|
31 |
Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 8, 1197-206.
DOI
ScienceOn
|
32 |
Woelk T, Sigismund S, Penengo L, Polo S (2007). The ubiquitination code: a signalling problem. Cell Division, 2, 11.
DOI
|